IRB Continuing Review Process: Annual Renewal Guide

IRB Continuing Review Process: Annual Renewal Guide

For researchers conducting ongoing clinical trials and studies, the IRB continuing review process is a critical regulatory requirement that ensures participant safety and protocol compliance throughout the life of a study. Understanding this process and preparing adequately can mean the difference between seamless continuation of your research and costly delays that impact timelines and budgets.

This comprehensive guide walks you through everything you need to know about IRB continuing review, from understanding when it's required to submitting a complete renewal application.

What Is IRB Continuing Review?

IRB continuing review is the periodic reassessment of approved research to ensure that the study continues to meet ethical standards and regulatory requirements. This process verifies that:

• The research continues to be scientifically valid
• Risks to participants remain minimized and reasonable
• The informed consent process remains adequate
• Data safety monitoring is appropriate
• Any protocol modifications are properly documented
• The research team maintains adequate qualifications and resources

While often called "annual renewal," the review frequency depends on the risk level of your study and may occur more frequently for higher-risk research.

When Is Continuing Review Required?

Under current FDA and HHS regulations (revised in 2018), continuing review requirements have become more focused. Understanding when continuing review is mandatory versus when it's not required can save time and resources.

Studies Requiring Continuing Review

Continuing review is required for research that:

1. Has not progressed to data analysis only - If you're still enrolling participants, conducting interventions, or interacting with participants, continuing review is necessary
2. Involves ongoing FDA-regulated research - Studies involving investigational drugs, biologics, or devices under FDA oversight typically require continuing review
3. Is determined by the IRB to need review - Even if not mandated by regulation, your IRB may require continuing review based on specific risk factors

Studies Exempt from Continuing Review

Research that has progressed to the point where:

• Data analysis is the only remaining activity
• No further participant interaction or intervention will occur
• No additional identifiable private information will be collected

These studies may not require continuing review, though you'll still need to submit a closure report when the study concludes.

Continuing Review Timelines: What You Need to Know

Understanding Your Approval Period

Your initial IRB approval letter will specify your approval expiration date. This date is critical - conducting research beyond this date without renewed approval constitutes a serious protocol violation and may be considered research misconduct.

For most studies, the approval period is: - One year for minimal to moderate risk studies - Six months or less for higher-risk protocols - Variable based on IRB determination for complex studies

When to Submit Your Continuing Review

Most IRBs require submission 30-60 days before your approval expiration date. However, best practices suggest:

• Submit 60-90 days early for complex multi-site studies
• Submit 45-60 days early for standard protocols
• Never wait until the last minute - unexpected questions or modifications can add review time

If your approval expires before continuing review is complete, you must suspend all research activities, including enrollment and interventions, until renewed approval is obtained.

Required Documentation for Continuing Review

Submitting a complete continuing review package is essential for timely approval. Missing or incomplete documentation is one of the common reasons IRB applications get rejected.

Core Documents

1. Continuing Review Application Form - Updated investigator information - Current study status (active, closed to enrollment, etc.) - Number of participants enrolled, completed, and withdrawn - Summary of study progress

2. Updated Protocol Include the current version incorporating all previously approved amendments. If no changes have been made since the last review, confirm you're using the most recently approved version.

3. Current Informed Consent Documents Provide all consent forms currently in use, including any language-specific versions or assent forms for pediatric populations.

4. Recruitment Materials Submit all current advertisements, social media posts, flyers, or other materials used to recruit participants.

5. Progress Report Your progress report should include: - Total number of participants enrolled at your site - Number of participants who completed the study - Number of participants who withdrew (with reasons) - Current enrollment status - Deviations from the protocol - Adverse events and unanticipated problems - Results of data safety monitoring - Multi-site enrollment numbers (if applicable)

Additional Documentation

Safety Reports Comprehensive summary of: - Adverse events (expected and unexpected) - Serious adverse events (SAEs) - Unanticipated problems involving risks to participants or others - Data Safety Monitoring Board (DSMB) reports, if applicable

Protocol Deviations and Violations Document any deviations from the approved protocol, including: - Description of each deviation - Whether it was anticipated or unanticipated - Corrective actions taken - Steps to prevent future occurrences

Updated Investigator Information - Current CVs and medical licenses - Updated financial disclosure forms - Current training certifications (CITI, GCP, etc.) - Changes to research team personnel

Supporting Documents - Updated investigator's brochure (for drug/device studies) - Revised sponsor protocols - DSMB reports or meeting minutes - Any relevant new literature affecting risk/benefit analysis

Special Considerations for Multi-Site Studies

If you're conducting multi-site research under a central IRB, continuing review becomes more streamlined but requires coordination:

• Ensure all sites provide local enrollment and safety data
• Coordinate timing so all sites remain in sync
• Understand the single IRB requirements for reliance agreements
• Maintain communication between the lead site and relying institutions

Common Pitfalls to Avoid

1. Missing the Submission Deadline

Late submissions can result in study suspension. Create calendar reminders 90, 60, and 30 days before your expiration date.

2. Incomplete Enrollment Data

Failing to provide accurate, up-to-date enrollment numbers raises red flags. Maintain ongoing tracking throughout the year.

3. Underreporting Adverse Events

Even if you've reported individual events as they occurred, provide a comprehensive summary in your continuing review.

4. Using Outdated Forms or Templates

Always download the most current forms from your IRB's website. Using outdated versions can delay review.

5. Inadequate Progress Justification

If enrollment is significantly below target, be prepared to explain why and provide plans for improvement or study closure.

The Review Process: What to Expect

Review Categories

Your continuing review may undergo:

Expedited Review Most continuing reviews for minimal risk studies qualify for expedited IRB review, which can be completed by the IRB chair or experienced reviewers without convening the full board.

Full Board Review Required for higher-risk studies or when significant issues have arisen. Understanding when you need full board review helps you plan appropriate timelines.

Possible Outcomes

1. Approved - Your study continues as is
2. Approved with Modifications - Minor changes required before continued approval
3. Deferred - Additional information needed before determination
4. Suspended - Serious concerns identified; research must stop
5. Terminated - IRB determines research should not continue

Best Practices for Smooth Continuing Review

Start Early

Begin compiling your continuing review submission at least 90 days before your expiration date. This allows time to gather safety reports, enrollment data, and updated documentation.

Maintain Ongoing Documentation

Don't wait until renewal time to organize your study files. Maintain: - Monthly enrollment logs - Running adverse event logs - Protocol deviation tracking - Team member training records

Communicate Proactively

If you anticipate any issues (low enrollment, unexpected safety signals, protocol changes), communicate with your IRB early. Surprises at continuing review can lead to delays or suspensions.

Ensure Complete Submissions

Before submitting, use the IRB's checklist to verify all required documents are included. Reference our detailed guide on IRB submission requirements for comprehensive preparation.

Prepare for Questions

Anticipate questions the IRB might ask: - Why is enrollment below target? - How are you addressing reported adverse events? - Are protocol deviations indicative of systemic issues? - Do recent publications change the risk/benefit profile?

Having answers prepared can expedite the review process.

After Approval: Next Steps

Update Your Records

• File the new approval letter in your regulatory binder
• Update your IRB approval expiration date in all tracking systems
• Notify your sponsor (if applicable) of renewed approval
• Inform all study team members

Calendar Your Next Review

Immediately schedule reminders for your next continuing review submission.

Implement Any Required Modifications

If approval came with conditions, implement changes promptly and document compliance.

Continuing Review for Specific Study Types

Different research types may have unique continuing review considerations:

Medical Device Trials For ongoing medical device clinical trials, include updated device malfunction reports and any manufacturer safety notifications.

Decentralized Trials When conducting decentralized clinical trials, document how remote monitoring and participant interaction continue to protect safety and privacy.

Conclusion: Partnership for Successful Research

The IRB continuing review process isn't simply a regulatory hurdle - it's an essential component of ethical research that protects participants and ensures scientific integrity. By understanding the requirements, preparing comprehensive documentation, and maintaining proactive communication with your IRB, you can ensure seamless continuation of your important research.

Streamline Your Continuing Review with Elemental IRB

At Elemental IRB, we understand that researchers need efficient, responsive IRB services that support rather than hinder scientific progress. Our streamlined continuing review process features:

• Clear submission guidelines and helpful templates
• Rapid turnaround times for expedited reviews
• Experienced reviewers who understand your research
• Dedicated support to answer questions and resolve issues quickly
• Transparent timelines and status tracking

Whether you're conducting a single-site study or managing a complex multi-center trial, Elemental IRB provides the expert oversight and responsive service you need. Contact us today to learn how we can support your ongoing research with professional, efficient continuing review services.